Inactive Instrument

Level Brands Inc Stock NYSE

US52730Q2093

Latest news : Level Brands Inc

Jul. 14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
Jul. 14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
Jul. 07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
Jul. 01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
Jun. 16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
May. 14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
May. 14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
May. 14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
Apr. 06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
Apr. 01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
Feb. 17	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
Feb. 17	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Feb. 02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI

More news

Last Transcript: Level Brands Inc

CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026

May. 14

More transcripts

Analysts' recommendations: Level Brands Inc

23-10-05	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
21-06-18	CBDMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Press Releases: Level Brands Inc

Jul. 27	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ
Jul. 24	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	PR
Jul. 14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	PR
Jul. 09	CbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation	PR
Jul. 07	CbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination	PR

More press releases

Managers and Directors: Level Brands Inc

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	2023-02-28
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	2018-12-31
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	2017-02-28
William Raines BRD	Director/Board Member	66	2019-04-18
Scott Stephen CHM	Chairman	60	2022-06-02

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

As early as today, start finding the best investment opportunities!

Maximize my profits

Market Cap	4.94M 4.3M 4M 3.67M 6.94M 472M 7.04M 47.16M 18.51M 235M 18.57M 18.16M 788M	P/E 2026 *	-2.48x	P/E 2027 *	-6.73x
Enterprise Value	4.94M 4.3M 4M 3.67M 6.94M 472M 7.04M 47.16M 18.51M 235M 18.57M 18.16M 788M	EV / Sales 2026 *	0.22x	EV / Sales 2027 *	0.21x
Free-Float	89.32%	Yield 2026 *	-	Yield 2027 *	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LEVEL BRANDS INC	-0.51%	+9.23%	-	-	4.94M
ELI LILLY AND COMPANY	-0.92%	-4.26%	+54.72%	+151.91%	1,030B
JOHNSON & JOHNSON	+0.93%	-2.00%	+56.69%	+54.08%	617B
ABBVIE INC.	-2.09%	-3.01%	+33.09%	+68.18%	455B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	350B
NOVARTIS AG	-0.14%	-0.24%	+34.41%	+39.01%	299B
ASTRAZENECA PLC	-0.69%	-0.30%	+11.55%	+12.93%	265B
NOVO NORDISK A/S	-7.37%	-4.40%	-2.54%	-43.87%	225B
AMGEN INC.	-0.49%	+2.64%	+30.79%	+64.83%	209B
GILEAD SCIENCES, INC.	-0.45%	+0.98%	+16.29%	+71.50%	163B
Average	-1.14%	+4.83%	+30.28%	+49.91%	401.41B
Weighted average by Cap.	-0.91%	+4.87%	+39.13%	+72.50%

	2026 *	2027 *
Net sales	22.15M 19.26M 17.92M 16.46M 31.08M 2.11B 31.56M 211M 82.92M 1.05B 83.2M 81.37M 3.53B	23.26M 20.22M 18.82M 17.28M 32.63M 2.22B 33.14M 222M 87.07M 1.11B 87.36M 85.44M 3.71B
Net income	-1.9M -1.65M -1.54M -1.41M -2.67M -182M -2.71M -18.14M -7.12M -90.39M -7.14M -6.99M -303M	-902K -784K -730K -670K -1.27M -86.11M -1.28M -8.6M -3.38M -42.87M -3.39M -3.31M -144M
Net Debt	-	-

Level Brands Inc Stock NYSE

Stocks

US52730Q2093

Pharmaceuticals

Valuation: Level Brands Inc

Latest news : Level Brands Inc

Last Transcript: Level Brands Inc

Analysts' recommendations: Level Brands Inc

Press Releases: Level Brands Inc

Quotes and Performance

Managers and Directors: Level Brands Inc

Other Pharmaceuticals

Financials

Company Profile